Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
Ibrahim AldossMary Caroline ClarkXiuli WangStephen Joel Formana Hematological Malignancies Research Institute,Duarte,CA,USAb Gehr Family Center for Leukemia Research,Duarte,CA,USAc Department of Hematology/Hematopoietic Cell Transplantation,Duarte,CA,USAd Department of Clinical and Translational Project Development,Duarte,CA,USAe T Cell Therapeutic Research Laboratories,City of Hope,Duarte,CA,USA
DOI: https://doi.org/10.1080/10428194.2023.2298712
2024-01-05
Leukemia & Lymphoma
Abstract:Older adults (≥55 years old) with B-cell acute lymphoblastic leukemia (B-ALL) have dismal outcomes with standard chemotherapy as the result of low treatment efficacy and considerable risks for treatment-related morbidity and mortality. There has been a recent success with the introduction of novel therapies, such as blinatumomab and inotuzumab, in the frontline therapeutic paradigm in older adults with B-ALL. However, these agents have their own challenges including the limited durability of remission, the need for additional concurrent chemotherapy and the prolonged course of treatment, and limited efficacy in the setting of extramedullary disease. Here, we hypothesize that the incorporation of chimeric antigen receptor (CAR) T cell therapy as a consolidation treatment in older adults with B-cell ALL in their first complete remission is the ideal setting to advance treatment outcomes by reducing treatment toxicity, enhancing remission durability, and expanding the use of this effective therapy in this age population.
oncology,hematology